













Sixth Report after enactment of the Stem Cell Act 
(StZG)  










1. The Central Ethics Committee for Stem Cell Research 
 
The Central Ethics Committee for Stem Cell Research (ZES) is an independent, 
interdisciplinary expert body that reviews and assesses applications for the import and use of 
human embryonic stem cells (hESCs). The activities of the Committee are governed by the 
Act ensuring the protection of embryos in conjunction with the import and use of human 
embryonic stem cells (Stammzellgesetz – StZG) of 28 June 2002 (BGBl. I p. 2277) 
(http://217.160.60.235/BGBL/bgbl1f/BGBl102042s 2277.pdf) (amended by the Act amending 
the Stem Cell Act of 14 August 2008 (BGBl. I p. 1708) 
(http://www.bgblportal.de/BGBL/bgbl1f/bgbl108s1708.pdf)) and the Regulations concerning 
the Central Ethics Committee for Stem Cell Research and the competent authority pursuant 
to the Stem Cell Act (ZES-Verordnung – ZESV) of 18 July 2002 (BGBl. I p. 2663) 
(http://217.160.60.235/BGBL/bgbl1f/ bgbl102s2663.pdf). ZES makes recommendations on 
the applications to the competent body pursuant to StZG, the Robert Koch Institute (RKI). 
 
The Committee’s 18 members and deputy members were appointed for the first time with the 
entry into force of StZG in 2002 for three years by the Federal Government. The third term of 
office began during the reporting period. Following the departure of one member, all 
members and deputies were reappointed and one new member was appointed. The 
members and deputy members of ZES perform their duties on a voluntary basis. Pursuant to 
§ 8 StZG, ZES currently has two members from the field of biology, three members from the 
field of medicine and four members from the fields of philosophical, medical and theological 
ethics. A deputy was appointed for each member (Table 1). Both the members and deputy 
members participate in the deliberations on the applications pursuant to ZESV.  
 
The task of ZES is to review applications for the import and use of human embryonic stem 
cells for their ethical acceptability pursuant to § 5 StZG and is specified in § 9 StZG. 
According to these provisions, an application must be accompanied by scientific 
substantiation that the research project serves research purposes of premium importance for 
the acquisition of scientific knowledge (§ 5 No. 1 StZG), that the scientific questions have 
been pre-examined in other systems including animal models (§ 5 No. 2a StZG) and that 
there are probably no alternatives to human embryonic stem cells in order to obtain the 
desired scientific knowledge (§ 5 No. 2b StZG). Both natural scientific and ethical aspects 
play an important role when reviewing and assessing the submitted applications. Based on 
four votes prepared from the circle of members and deputy members from the various fields, 
ZES summarises the results in a written opinion. 
 
The work of ZES requires the ongoing monitoring and consideration of the latest scientific 
developments in the field of stem cell research. Here, the focus is particularly on research on 
pluripotent cells of various origins. ZES followed with interest the debates in the run-up to the 
amendment to the Stem Cell Act. Committee members had an opportunity, especially at 
presentations and parliamentary public hearings, to input their expertise concerning scientific 
developments and ethical problems of stem cell research. The amendment to the Stem Cell 
Act that entered into force on 21 August 2008 placed, amongst other things, the cooperation 
of German research groups with European partners on a sound legal basis through the 
amendment to § 13. 
 
The annual report of ZES, which is published by the Federal Ministry of Health (BMG) (§ 14 
ZESV), and the previous ZES reports can be accessed on the BMG website 
(www.bmg.bund.de). 






Table 1: Members and Deputy Members of the Central Ethics Committee for Stem Cell Research (ZES), status 
November 2008 
Field Member Deputy Member 
 
Prof. Dr. rer. nat. Hans R. Schöler 




Prof. Dr. rer. nat. Martin Zenke 
Institut für Biomedizinische Technologien 





Prof. Dr. rer. nat. Anna M. Wobus 
(Deputy Chairman) 










Prof. Dr. phil. Ludwig Siep 
(Chairman) 
Philosophisches Seminar 
Westfälische Wilhelms-Universität Münster 
 
 
Prof. Dr. phil. Jan Beckmann 
Institut für Philosophie 
FernUniversität in Hagen 
Ethics 
 
Prof. Dr. med. Claudia Wiesemann 





Prof. Dr. med. Giovanni Maio, 
Institut für Ethik und Geschichte der Medizin 
Albert-Ludwigs-Universität Freiburg 
 
Prof. Dr. med. Gustav Steinhoff 
Klinik und Poliklinik für Herzchirurgie  
Universität Rostock  
 
 




Prof. Dr. med. Marion B. Kiechle 
(Deputy Chairman) 
Frauenklinik und Poliklinik 
Klinikum rechts der Isar 
Technische Universität Munich 
 
 
Prof. Dr. med. Ricardo E. Felberbaum 
Frauenklinik 
Klinikum Kempten Oberallgäu 
Medicine 
 
Prof. Dr. med. Anthony D. Ho 
Med. Universitätsklinik und Poliklinik 




Prof. Dr. med. Ulf Rapp 
Institut für Medizinische Strahlenkunde  





Prof. Dr. theol. Klaus Tanner 
Wissenschaftlich-Theologisches Seminar 




Prof. Dr. theol. Hartmut Kreß 
Evangelisch-Theologische Fakultät 
Abteilung für Sozialethik und  






Prof. Dr. theol. Dr. phil. Antonio Autiero 
Seminar für Moraltheologie 
Katholisch-Theologische Fakultät 
Westfälische Wilhelms-Universität Münster 
 
Prof. Dr. theol. Konrad Hilpert 
Lehrstuhl für Moraltheologie 
Katholisch-theologische Fakultät 
Ludwig-Maximilians-Universität Munich 






2. Deliberation and review of applications pursuant to § 5 StZG during the 
reporting period  
 
During the reporting period ZES held eight meetings at which a total of 10 applications for the 
import and/or use of human embryonic stem cells and one extension application for an 
already approved project were extensively discussed. All the applications were viewed 
positively by ZES. Two applications, for which ZES had already handed down a positive 
opinion during the previous reporting period, were only approved by the Robert Koch Institute 
during the current reporting period. As, pursuant to § 11 StZG, data on applications may only 
be published after approval, this report contains information on these two applications. Table 
2 gives an overview of the applications that were viewed positively by ZES and approved by 
RKI during the reporting period.  
 
The subject of the first project (Approval 25) is the systematic examination of molecular 
processes on the levels of the transcriptome, the proteome and the epigenome that steer the 
development of pluripotent stem cells in early differentiation stages. The starting point for this 
is the cultivation of human embryonic stem cells under defined chemical conditions. 
 
The second research project (Approval 26) addresses the development of improved methods 
for the cultivation and differentiation of pluripotent human embryonic stem cells. By means of 
magnetic activated cell sorting, MACS, that involves separation of human embryonic stem 
cells by using suitable surface markers, highly purified populations of human embryonic stem 
cells and differentiated cells can be obtained and characterised.  
 
In the fourth project (Approval 28) a comparison of the differentiation potential of human 
embryonic stem cells and induced pluripotent stem cells (iPS cells) in cardiac tissue using 
various scaffold materials will be performed. The main question is whether human cardiac 
tissue suitable for transplantation can be produced from either pluripotent cell type. Hence, 
on various carrier materials and in three-dimensional scaffolds, differentiation into cardiac 
cell types is to be optimised using different methods and protocols. There are also plans to 
transplant tissue complexes differentiated in vitro into a rat myocardial infarct model.  
 
Two projects look at the neuronal differentiation of human embryonic stem cells: 
One project (Project 3, Approval 27) focuses on the examination of the early neuronal 
differentiation of man, in particular neural tube development on a three-dimensional matrix. It 
is expected that complex three-dimensional cellular structures will be formed. The research 
will seek to clarify whether differentiation during the development of the structures can be 
controlled and whether the spatial arrangement of the cells in the cell structures can be 
influenced during cultivation. 
 
Another project (Project 5, Approval 29) plans to establish an in vitro model system with the 
properties of human neuronal networks. It is to be used in studies on the developmental 
biology of human neurons and to examine neuroactive substances. The in vitro system is 
also to serve as the basis for models of neurodegenerative diseases that could be used to 
compare transplantation of neuronal cells derived from human embryonic stem cells or from 
human umbilical cord blood cells.  
 





Number Applicant Research area 
 









Studies on transitions of human embryonic stem 










Development of magnetic activated methods for 
the enrichment of pluripotent human embryonic 




Frau Prof. Dr. Elly M. Tanaka 
Technische Universität 




Establishment of a three-dimensional culture 
system for early human neural precursor cells 
to examine aspects of the development of the 









Comparison of bioengineering of vascularised 
cardiac tissue for cell transplantation using 











Production and characterisation of functional 









Comparative study of adult spermatogonial 
and human embryonic stem cells. 
Differentiation of human embryonic stem cells 




Prof. Dr. Jürgen Hescheler 
Institut für Neurophysiologie 
der Universität zu Köln 
 
 
Examination of the effects of harmful 
influences on differentiating human embryonic 
stem cells. Differentiation of hepatocytes from 





Prof. Dr. Jan Hengstler 




Differentiation of human embryonic stem cells 
into hepatocyte-like cells and the study of their 
suitability for the development of improved in 





Prof. Dr. Harald von Melchner 




Production of human embryonic stem cell 
libraries through conditional gene trap 




Frau Dr. Anja Moldenhauer 
Institut für Transfusions-
medizin, Charité Berlin 
 
Differentiation of human embryonic stem cells 
into erythrocytes and thrombocytes 14.07.2008 
 













Prof. Dr. Oliver Brüstle 
Institut für Rekonstruktive 
Neurobiologie, 
Universitätsklinikum Bonn 
Differentiation and transplantation of neural 





Table 2: Overview of projects that were approved by RKI during the reporting period following a definitive, positive 
assessment by ZES. The numbers in brackets in the left column correspond to the approval numbers in the RKI 




Project 6 (Approval 30) consists of two separate parts. The first part pursues a new 
perspective for the production of pluripotent cells. The intention is to isolate human 
spermatogonial stem cells (SSCs) from adult testicular tissue and to compare them with 
human embryonic stem cells. Given that multipotent adult germline stem cells (maGSCs) 
with specific properties of pluripotent cells can be isolated and cultivated from murine testis 
tissue, cell lines are to be established in a similar manner from human testicular tissue in 
order to examine them for the presence of the characteristics of pluripotent cells. 
Comparative studies of human embryonic stem cells and human SSCs are expected to 
produce knowledge about the ability of human SSCs of being reprogrammed into pluripotent 
cells. 
In the second part the project conditions for the differentiation of human embryonic stem cells 
into precursors of cardiac cells are to be established. In this context cardiac precursor cells 
are to be identified using a receptor for the vascular endothelial growth factor (VEGFR-2), 
then isolated and differentiated into cardiac cells. 
 
Two of the research projects reviewed by ZES aim to differentiate human embryonic stem 
cells into cells with the properties of human hepatic cells. They are part of the ESNATS 
project supported by the European Community which promotes the development of new test 
protocols for the testing of toxic substances.  
 
With the help of various differentiation protocols Project 8 (Approval 32) aims to develop 
human embryonic stem cells into hepatocyte-like cells, characterise them morphologically, 
biochemically and functionally, and then examine them for their ability to metabolise various 
substances. Furthermore, the properties of hepatocyte-like cells are to be compared with 
those of primary human hepatocytes and of hepatocyte-like cells derived from somatic stem 
and precursor cells. After optimisation of the differentiation protocols, the cells are to be 
cultivated in specific co-culture systems together with other cells (e.g. neurons) 
manufactured from human embryonic stem cells by other ESNATS project partners. The 
latter are to be used as target cells to test substances which are only toxified after metabolic 
degradation by hepatocytes.   
 
The second of the two EU research projects (Project 7, Approval 31) consists of two parts. In 
the first part human embryonic stem cells are to be developed into hepatocyte-like cells using 
a differentiation protocol based on the enrichment of differentiated cells involving the 
expression of a reporter gene expressed under the control of a tissue-specific promotor. In 
the second part, cells from human embryonic stem cells spontaneously differentiating inside 
embryoid bodies are to be exposed to various noxae with potentially teratogenic effects. 
Differences in the gene expression pattern of the cells, which are due to the differentiation-
dependent, time-dependent and dose-dependent impact of the specific noxa, are to be 
identified on the RNA and protein levels. The intention is to create foundations for new in 




vitro test systems for teratogenic substances and medical active substances with unknown 
effects on development processes. 
 
Systems of this kind for in vitro drug testing and for examining the metabolic degradation of 
potential pharmaceuticals could help to estimate the risk potential of drugs for use in humans 
and reduce this potential in future. 
 
Another research project (Project 9, Approval 33) aims at quantitatively analysing gene 
functions of human embryonic stem cell lines. To this end a library of mutated human 
embryonic stem cell lines is to be established in which one gene has mutated in each of the 
cell lines. The gene trap strategy used, based on the use of retroviral vectors, should 
potentially allow to mutate all genes in the human genome. In this way genes that play a role 
in human disease could be identified and characterised. 
 
The subject of Project 10 (Approval 34) is the harnessing of haematopoietic precursor cells 
from human embryonic stem cells in order to differentiate them into specific blood cells, i.e. 
erythrocytes and thrombocytes. The goal of the project is to obtain insights into factors and 
mechanisms involved in the embryonic development of haematopoietic cells and to establish 
a basis for reliable, reproducible protocols for the in vitro differentiation of human embryonic 
stem cells into cells of the erythroid and thrombocytic lines. The studies are to involve a 
comparison with haematopoietic cells generated from umbilical cord blood 
 
An application for further work has been submitted for the first research project with human 
embryonic stem cells from 2002. This required an extension to the RKI approval and also 
renewed discussion by the Committee. The work spanning several years on the neural 
differentiation of human embryonic stem cells is to be used in the extended application to 
apply the knowledge acquired to studies on the treatment of epilepsy. Human embryonic 
stem cells and neural precursor cells derived from them are to be genetically modified in 
such a manner that they produce factors with anti-epileptic properties. Preclinical 
investigations are to be conducted on the basis of the transplantation of neural precursor 
cells derived from human embryonic stem cells in various rodent epilepsy models. They are 
supposed to produce information on later human therapeutic effects. Furthermore, there are 
plans to monitor the functional integration of the transplanted cells in the nerve tissue of the 
recipient animal using a molecular reporter system. In this way specific regions in the brain 
could be identified which are particularly suitable for the transplantation of neural cells.  
 
Further information on the content of the projects supported by ZES and approved by RKI 
can be found in the RKI register 
(http://www.rki.de/DE/Content/Gesund/Stammzellen/Register/register__node.html). The main 
ZES arguments concerning the superior interest of the research projects, their sufficient 
preliminary clarification and the need to use human embryonic stem cells have been taken 
over into the assessment of the research projects by RKI.  
  
In its work now spanning six years, ZES has deliberated on a total of 38 applications for the 
import and/or use of human embryonic stem cells and three applications for extensions to 
already approved projects. In total 41 opinions were handed down, 39 of them were positive. 
All the projects supported by ZES were approved by RKI.  
 
In Germany 26 working groups are currently engaged in research involving human 
embryonic stem cells. Experimental findings from the approved projects of six groups have 
been included in 18 scientific publications.  
  
In 2008 the Committee definitively reviewed eight applications from research groups who had 
not previously worked with human embryonic stem cells as well as three applications by 
groups who already have permission to work with human embryonic stem cells. These 




applications were already received during the first six months of the reporting period and 
required extensive deliberations by ZES.  
 
On the occasion of its fifth anniversary, ZES invited members of parliament and other 
interested parties to a colloquium in September 2007 which looked at the situation of stem 
cell research and provided insight into the research projects approved in Germany. The 
papers that documented the national and international research situation were published in 





Outlook and final comments 
 
Based on their experience drawn from the discussion of these applications, ZES sees 
opportunities for cell biological basic and applied medical research with human embryonic 
stem cells in several areas. In the field of basic research this involves more particularly 
analysis of the development processes of human cells. In this context basic research can 
also achieve indirect success by producing results that can be used for other, related 
research areas. This applies in particular to research on other stem cells, 
pharmacotoxicology or active substance research. Basic research of premium importance 
can open up entirely new research and application paths. 
International research on human embryonic stem cells has become an established research 
area. The cultivation and differentiation of human embryonic stem cells has been developed 
on using standardised methods. By contrast, clinical applications or regenerative therapies 
based on human embryonic stem cells are not likely in the near future. The problem remains 
that cells differentiated from human embryonic stem cells may be contaminated with human 
embryonic stem cells which can lead to the development of tumours (teratoma, 
teratocarcinoma). Nonetheless, neural cells derived from human embryonic stem cells can 
be harnessed already today without any contamination with undifferentiated stem cells. The 
general expectation is, therefore, that the first clinical trials can be developed with 
transplantable cells derived from human embryonic stem cells for the regeneration of neural 
tissue.  
Human embryonic stem cells play an increasing role as the standard in comparative studies 
with other pluripotent cell types, e.g. parthenogenetic embryonic stem cells (pESC), germline 
stem cells (GSC) and induced pluripotent stem cells (iPS). These “new” pluripotent cell types 
are increasingly under discussion as a potential source of cells for harnessing patient-
specific cells. All the same, in the case of all donor cells derived from pluripotent cells, 
impurities with undifferentiated cells may still lead to the formation of tumours. In particular 
induced pluripotent stem cells, iPS cells, take on a special role in the field of research 
concerning pathogenesis mechanisms of human diseases. This is because, after 
reprogramming with the help of pluripotency genes, pluripotent stem cells from ordinary body 
cells (e.g. fibroblasts, harnessed from patients with a genetic disease) can be isolated and 
undergo molecular and cell biological in vitro analysis. It is expected that these research 
activities will produce important findings for the diagnosis and treatment of numerous 
diseases.  
Furthermore, the use of human embryonic stem cells for the development of medical active 
substances, for the testing of medicines and for toxicity studies seems to be imminent. This 
is directly obvious from applications submitted to ZES, e.g. within the framework of the EU 
programmes, but also from international developments. Toxicological and pharmacological 
tests in human embryonic stem cells will also supply more reliable results for man than 
studies in animals or animal cells. This moves in the same direction as EU support for 
research, various streams in the ethical debate and research projects aiming to reduce the 
number of animal experiments and the high consumption of laboratory animals by 
establishing test systems with human embryonic stem cells. In particular the EU Regulation 
1907/2006 REACH throws up major challenges for EU Member States, including Germany.  




In this context, human embryonic stem cell lines of this kind that are established, cultured 
and stored, for instance in European or international stem cell banks, will become 
increasingly important for recognised test methods.  
 
The StZG permits the import and use of human embryonic stem cells pursuant to § 4 para 2 
StZG for research purposes. Against the backdrop of domestic and foreign research projects, 
there will have to be, in future, more exact clarification of whether and, if so, to what extent 
the broad use of human embryonic stem cells, e.g. within the framework of safety tests for 
medicinal products, is to be seen as a research goal within the intendment of the Stem Cell 
Act. For test purposes differentiation trials with embryonic stem cells would have to be 
staged regularly, for instance for studies on embryotoxicology.  
 
 
The Sixth Report was unanimously approved at the 43rd ordinary meeting of ZES on 21 
January 2009. 
